Cargando…

Psychotherapy employed additionally to Psychopharmacotherapy is not related to Better Treatment Outcome in Major Depressive Disorder

INTRODUCTION: Although numerous effective antidepressant (AD) strategies are available for the treatment of major depressive disorder (MDD), many patients do not achieve satisfactory treatment response. OBJECTIVES: The aims of the present European, cross-sectional, multicenter, naturalistic study we...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bartova, L., Fugger, G., Dold, M., Mitschek, M., Zohar, J., Mendlewicz, J., Souery, D., Montgomery, S., Fabbri, C., Serretti, A., Kasper, S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Cambridge University Press 2022
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9567182/ http://dx.doi.org/10.1192/j.eurpsy.2022.229

Ejemplares similares

Clinical Correlates and Outcome of Major Depressive Disorder and Comorbid Migraine: A Report of the European Group for the Study of Resistant Depression
por: Fugger, Gernot, et al.
Publicado: (2020)

Clinical correlates of augmentation/combination treatment strategies in major depressive disorder
por: Dold, M., et al.
Publicado: (2018)

Sex‐related effects in major depressive disorder: Results of the European Group for the Study of Resistant Depression
por: Bartova, Lucie, et al.
Publicado: (2021)

Age as a moderating factor of treatment resistance in depression
por: Kautzky, Alexander, et al.
Publicado: (2023)

The Choice of Either Quetiapine or Aripiprazole as Augmentation Treatment in a European Naturalistic Sample of Patients With Major Depressive Disorder
por: Bartova, Lucie, et al.
Publicado: (2021)

Major Depression and the Degree of Suicidality: Results of the European Group for the Study of Resistant Depression (GSRD)
por: Dold, Markus, et al.
Publicado: (2018)

The sociodemographic and clinical profile of patients with major depressive disorder receiving SSRIs as first-line antidepressant treatment in European countries
por: Fugger, Gernot, et al.
Publicado: (2022)

PS75. Psychopharmacoepidemiology of Major Depressive Disorder in European Tertiary Psychiatric Treatment Centers
por: Bartova, Lucie, et al.
Publicado: (2016)

Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study
por: Kautzky, A., et al.
Publicado: (2018)

The Genetics of Treatment-Resistant Depression: A Critical Review and Future Perspectives
por: Fabbri, Chiara, et al.
Publicado: (2018)

Dimensions of Delusions in Major Depression: Socio-demographic and Clinical Correlates in an Unipolar-Bipolar Sample
por: Zaninotto, Leonardo, et al.
Publicado: (2015)

The Impact of BDNF Polymorphisms on Suicidality in Treatment-Resistant Major Depressive Disorder: A European Multicenter Study
por: Schosser, Alexandra, et al.
Publicado: (2017)

PS87. An update on prediction of treatment outcome in treatment resistant depression
por: Kautzky, Alexander, et al.
Publicado: (2016)

Case report: Hyperactive delirium after a single dose of zolpidem administered additionally to psychopharmacotherapy including clozapine
por: Preiss, Maximilian, et al.
Publicado: (2023)

Body mass index and clinical outcomes in individuals with major depressive disorder: Findings from the GSRD European Multicenter Database
por: Kraus, Christoph, et al.
Publicado: (2023)

A polygenic predictor of treatment-resistant depression using whole exome sequencing and genome-wide genotyping
por: Fabbri, Chiara, et al.
Publicado: (2020)

Silexan for treatment of anxiety and depression in the context of COVID-19
por: Bartova, Lucie, et al.
Publicado: (2023)

Polygenic risk scores for neuropsychiatric, inflammatory, and cardio‐metabolic traits highlight possible genetic overlap with suicide attempt and treatment‐emergent suicidal ideation
por: Fanelli, Giuseppe, et al.
Publicado: (2022)

Diagnostic and psychopharmacotherapy in the general practictioner practice
por: Kraxner, F. H.
Publicado: (2023)

Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment
por: Dold, Markus, et al.
Publicado: (2020)

Role of Donepezil in Autism: Its Conduciveness in Psychopharmacotherapy
por: Srivastava, Rohit Kant, et al.
Publicado: (2011)

Silexan for treatment of psychiatric manifestations in the context of COVID-19: a case series
por: Bartova, L., et al.
Publicado: (2023)

Psychodynamically Oriented Psychopharmacotherapy: Towards a Necessary Synthesis
por: Iannitelli, Angela, et al.
Publicado: (2019)

A Guide for Psychopharmacotherapy during COVID-19 Outbreak
por: Salehi, Mona
Publicado: (2020)

Modern approaches to psychopharmacotherapy of anorexia nervosa and bulimia nervosa
por: Belokrylov, I., et al.
Publicado: (2021)

Selective outcome reporting across psychopharmacotherapy randomized controlled trials
por: Lancee, Michelle, et al.
Publicado: (2021)

Psychopharmacotherapy of Obsessive-Compulsive Symptoms within the Framework of Tourette Syndrome
por: Rothenberger, Aribert, et al.
Publicado: (2019)

Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy
por: Mehler-Wex, Claudia, et al.
Publicado: (2009)

Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions
por: Ragnhildstveit, Anya, et al.
Publicado: (2022)

Genetics and major depressive disorder: clinical implications for disease risk, prognosis and treatment
por: Fabbri, Chiara, et al.
Publicado: (2020)

Genetics of Treatment Outcomes in Major Depressive Disorder: Present and Future
por: Fabbri, Chiara, et al.
Publicado: (2020)

Impulsivity across severe mental disorders: a cross-sectional study of immune markers and psychopharmacotherapy
por: Hjell, Gabriela, et al.
Publicado: (2023)

Employing Psychotherapy Across Cultures and Contexts
por: Jacob, K. S.
Publicado: (2013)

How to Utilize Clinical and Genetic Information for Personalized Treatment of Major Depressive Disorder: Step by Step Strategic Approach
por: Fabbri, Chiara, et al.
Publicado: (2020)

Various neuromodulation methods including Deep Brain Stimulation of the medial forebrain bundle combined with psychopharmacotherapy of treatment-resistant depression—Case report
por: Rymaszewska, Joanna, et al.
Publicado: (2023)

Beneficial effects of Silexan on co-occurring depressive symptoms in patients with subthreshold anxiety and anxiety disorders: randomized, placebo-controlled trials revisited
por: Bartova, Lucie, et al.
Publicado: (2022)

Possible Modulatory Role of ARC Gene Variants in Mood Disorders
por: Crisafulli, Concetta, et al.
Publicado: (2021)

Improving Employment Through Interpersonal Psychotherapy: A Case Series of Patients With Treatment-Refractory Depression
por: Katagiri, Takeshi, et al.
Publicado: (2021)

A New Characterization of Mental Health Disorders Using Digital Behavioral Data: Evidence from Major Depressive Disorder
por: Taliaz, Dekel, et al.
Publicado: (2021)

Neural Implications of Psychotherapy, Pharmacotherapy, and Combined Treatment in Major Depressive Disorder
por: Schwartz, Thomas L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jakhcvl7073vnjrdcuo60njt8t